Press Releases
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
Oct 26, 2022
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
Oct 19, 2022
Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients
Oct 12, 2022
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
Sep 28, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
Sep 23, 2022
Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab
Sep 20, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
Sep 16, 2022
Tiziana Life Sciences Announces Grant received by the Brigham and Women’s Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis
Sep 15, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
Sep 09, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
Aug 25, 2022
Displaying 41 - 50 of 450